Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

106.63 -0.26 (-0.24%)
Streaming Delayed Price Updated: 11:47 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abbott Laboratories

< Previous 1 2 3 4 5 Next >
Abbott Laboratories Outlook is Healthy: Buy the Dip
Abbott Laboratories had a steady quarter, producing growth, better-than-expected earnings, and raising the guidance. Analysts see the stock moving higher. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson is as Cheap as it’s Going to Get
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely. 
Via MarketBeat
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
Exposures Death
Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning
Via Investor Brand Network
Abbott Laboratories (NYSE: ABT) Highlighted for Surprising Price Action
Via Investor Brand Network
Medtronic is a Dividend Aristocrat That Keeps Gaining
A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector 
Via MarketBeat
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
4 med tech stocks with improving prognosis for 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025. 
Via MarketBeat
Exposures COVID-19
Less Is More: Abbott’s Approach to Packaging Innovation
Via ACCESSWIRE
Abbott Joins Billion Dollar Roundtable
Via ACCESSWIRE
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Medtronic receives FDA approval for deep brain stimulation system
Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS) 
Via MarketBeat
Exposures Product Safety
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
From Tandem Diabetes Care, Inc.
Via Business Wire
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
Medtronic: oversold, overextended high yield reversal in play
The reversal in Medtronic has been brewing for some time but is gaining traction after strong second quarter earnings that came with improved guidance 
Via MarketBeat
Exposures COVID-19
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
Dividend aristocrats Caterpillar, NextEra, and Clorox have shown resilience in challenging times. These may offer opportunities as they are trading off highs. 
Via MarketBeat
Exposures COVID-19
The Value Deepens for Medtech Stocks: Reversal Imminent
MedTech stocks are performing well and supported by pent-up demand, yet share prices are trading at significant and often historical lows. 
Via MarketBeat
Oversold and Overextended, Abbott Laboratories is a Great Buy
Abbott Laboratories rises on solid results and guidance; the value and dividend are at the best levels in years, and the sell-side is buying. 
Via MarketBeat
Exposures COVID-19
Lumentum Lights Up on the AI and ML Surge
Optical and photonics manufacturer Lumentum Holdings Inc. (NASDAQ: LITE) provides optical components and lasers to data centers, cloud providers, telecoms 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Stocks to Benefit from the Aging Population
The growth of the aging population is entirely predictable, which makes now an ideal time to consider these two health and wellness stocks 
Via MarketBeat
Topics Retirement
Exposures COVID-19 Pension
A Significant Reversal is in Sight for These 5 Med Tech Companies
Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand. 
Via MarketBeat
5 Good Reasons it's Time to Buy High-Yield Dividend King 3M
3M settled the ear plug lawsuit, clearing the path forward. The stock offers investors a high yield and value that may be too hard to pass up 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher
Strong Q2 earnings performance propelled DexCom higher. Investors cheered the glucose monitoring leader's bullish sales view and international expansion plans. 
Via MarketBeat
Johnson & Johnson's Inflection Point: What it Means for Investors
Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories Has the Prescription for Higher Share Prices
Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating. 
Via MarketBeat
Exposures COVID-19
Agilent Technologies Stock: Ready to Rise off the Floor
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider. 
Via MarketBeat
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next. 
Via MarketBeat
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.